AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
ASPX was delisted on the 4th of May, 2015.
47 hedge funds and large institutions have $271M invested in AUSPEX PHARMACEUTICALS INC COM STK (DE) in 2014 Q1 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$58.3M |
| 2 |
DM
Deerfield Management
New York
|
+$53.4M |
| 3 |
Millennium Management
New York
|
+$24.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$13.2M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$10.8M |
Top Sellers
ASPX Hedge Fund Activity: Q1 2014 in Review
47 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) for Q1 2014, worth a combined $271M.
Buyers outnumbered sellers: 47 funds opened new ASPX positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $58.3M.
- 47 institutional investors held AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $271M of AUSPEX PHARMACEUTICALS INC COM STK (DE) stock for Q1 2014.
- 47 funds opened new AUSPEX PHARMACEUTICALS INC COM STK (DE) positions in Q1 2014 and 0 closed out, a net change of +47 holders.
- The largest AUSPEX PHARMACEUTICALS INC COM STK (DE) buyer in Q1 2014 was Fidelity Investments, an estimated $58.3M added.
Based on aggregated 13F filings for Q1 2014.